About us
Meet Philippe Herman, CEO of Immunochem
Hello, I’m Philippe Herman ! I have been evolving for +12 years on the intersection of biophysics and computational biology.
I authored 20 papers, a PNAS and was invited to write a Science perspective around the hospital-acquired infections.
I am passionate about how technique can help Science. During my research, I needed of precisely designed molecules against my antigens of interests.
This inspired me to develop IMMUNOCHEM’s EVOBodies™ platform, making it accessible to our clients and partners.
Our technology and services
- Our technology
We start from a validated antibody, already screened for liabilities, and design the CDR loops that grip your target
- All services
Nanobody, antibody, miniprotein binder and peptide discovery, de novo design and humanization
Start designing better antibodies
We design developable antibodies using AI in under 6 weeks, wet-lab validated in 9 weeks, from your antigen sequence. No immunisation, no phage display, no animal.